SkinBioTherapeutics Management
Management criteria checks 4/4
SkinBioTherapeutics' CEO is Stuart Ashman, appointed in Jul 2019, has a tenure of 5.5 years. total yearly compensation is £324.64K, comprised of 97.8% salary and 2.2% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth £48.44K. The average tenure of the management team and the board of directors is 2.2 years and 5.6 years respectively.
Key information
Stuart Ashman
Chief executive officer
UK£324.6k
Total compensation
| CEO salary percentage | 97.8% |
| CEO tenure | 5.5yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.2yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
Here's Why We're Watching SkinBioTherapeutics' (LON:SBTX) Cash Burn Situation
Mar 28
Will SkinBioTherapeutics (LON:SBTX) Spend Its Cash Wisely?
Sep 30Is SkinBioTherapeutics (LON:SBTX) In A Good Position To Deliver On Growth Plans?
Jun 11We Think SkinBioTherapeutics (LON:SBTX) Can Afford To Drive Business Growth
Feb 16We're Not Worried About SkinBioTherapeutics' (LON:SBTX) Cash Burn
Sep 29Companies Like SkinBioTherapeutics (LON:SBTX) Can Afford To Invest In Growth
Mar 23How Much Are SkinBioTherapeutics Plc (LON:SBTX) Insiders Taking Off The Table?
Jan 29Companies Like SkinBioTherapeutics (LON:SBTX) Are In A Position To Invest In Growth
Dec 07
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | UK£325k | UK£318k | -UK£3m |
| Mar 31 2024 | n/a | n/a | -UK£3m |
| Dec 31 2023 | n/a | n/a | -UK£3m |
| Sep 30 2023 | n/a | n/a | -UK£3m |
| Jun 30 2023 | UK£382k | UK£364k | -UK£3m |
| Mar 31 2023 | n/a | n/a | -UK£3m |
| Dec 31 2022 | n/a | n/a | -UK£3m |
| Sep 30 2022 | n/a | n/a | -UK£3m |
| Jun 30 2022 | UK£368k | UK£319k | -UK£3m |
| Mar 31 2022 | n/a | n/a | -UK£2m |
| Dec 31 2021 | n/a | n/a | -UK£2m |
| Sep 30 2021 | n/a | n/a | -UK£2m |
| Jun 30 2021 | UK£373k | UK£323k | -UK£1m |
| Mar 31 2021 | n/a | n/a | -UK£1m |
| Dec 31 2020 | n/a | n/a | -UK£1m |
| Sep 30 2020 | n/a | n/a | -UK£1m |
| Jun 30 2020 | UK£276k | UK£234k | -UK£2m |
| Mar 31 2020 | n/a | n/a | -UK£1m |
| Dec 31 2019 | n/a | n/a | -UK£1m |
| Sep 30 2019 | n/a | n/a | -UK£1m |
| Jun 30 2019 | UK£265k | UK£52k | -UK£1m |
Compensation vs Market: Stuart's total compensation ($USD401.74K) is about average for companies of similar size in the UK market ($USD352.54K).
Compensation vs Earnings: Stuart's compensation has been consistent with company performance over the past year.
CEO
Stuart Ashman (58 yo)
5.5yrs
Tenure
UK£324,642
Compensation
Mr. Stuart John Ashman serves as Chief Executive Officer of SkinBioTherapeutics since July 2019 and serves as Executive Director at SkinBioTherapeutics Plc since April 18, 2019. Since 2014, he served as Ch...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 5.5yrs | UK£324.64k | 0.12% £ 48.4k | |
| CFO, Secretary & Director | 2.6yrs | UK£227.99k | 0.067% £ 26.8k | |
| Head of Formulations | 1.7yrs | no data | no data | |
| Group Financial Controller | 1.8yrs | no data | no data |
2.2yrs
Average Tenure
Experienced Management: SBTX's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 5.8yrs | UK£324.64k | 0.12% £ 48.4k | |
| CFO, Secretary & Director | 2.6yrs | UK£227.99k | 0.067% £ 26.8k | |
| Independent Non-Executive Director | 7.8yrs | UK£36.10k | 0.079% £ 31.7k | |
| Independent Non-Executive Chairman | 8.3yrs | UK£71.02k | 0.25% £ 98.1k | |
| Scientific Adviser | 5.5yrs | UK£66.42k | no data | |
| Independent Non-Executive Director | 2.8yrs | UK£26.25k | 0.019% £ 7.7k |
5.6yrs
Average Tenure
58yo
Average Age
Experienced Board: SBTX's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 01:56 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SkinBioTherapeutics plc is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Donnellan | Cavendish |
| Christopher Donnellan | Cavendish Historical (Cenkos Securities) |